Literature DB >> 20233708

Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.

Lei Gu1, Paraskevi Vogiatzi, Martin Puhr, Ayush Dagvadorj, Jacqueline Lutz, Amy Ryder, Sankar Addya, Paolo Fortina, Carlton Cooper, Benjamin Leiby, Abhijit Dasgupta, Terry Hyslop, Lukas Bubendorf, Kalle Alanen, Tuomas Mirtti, Marja T Nevalainen.   

Abstract

There are no effective therapies for disseminated prostate cancer. Constitutive activation of Stat5 in prostate cancer is associated with cancer lesions of high histological grade. We have shown that Stat5 is activated in 61% of distant metastases of clinical prostate cancer. Active Stat5 increased metastases formation of prostate cancer cells in nude mice by 11-fold in an experimental metastases assay. Active Stat5 promoted migration and invasion of prostate cancer cells, and induced rearrangement of the microtubule network. Active Stat5 expression was associated with decreased cell surface E-cadherin levels, while heterotypic adhesion of prostate cancer cells to endothelial cells was stimulated by active Stat5. Activation of Stat5 and Stat5-induced binding of prostate cancer cells to endothelial cells were decreased by inhibition of Src but not of Jak2. Gene expression profiling indicated that 21% of Stat5-regulated genes in prostate cancer cells were related to metastases, while 7.9% were related to proliferation and 3.9% to apoptosis. The work presented here provides the first evidence of Stat5 involvement in the induction of metastatic behavior of human prostate cancer cells in vitro and in vivo. Stat5 may provide a therapeutic target protein for disseminated prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233708      PMCID: PMC6260789          DOI: 10.1677/ERC-09-0328

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  43 in total

1.  Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

Authors:  Yukiyasu Ozawa; Ann H Williams; Myka L Estes; Norimasa Matsushita; Frank Boschelli; Richard Jove; Alan F List
Journal:  Leuk Res       Date:  2008-01-07       Impact factor: 3.156

2.  PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro.

Authors:  Tommi J Ahonen; Pirkko L Härkönen; Hallgeir Rui; Marja T Nevalainen
Journal:  Endocrinology       Date:  2002-01       Impact factor: 4.736

Review 3.  Interactions between cancer cells and the endothelium in metastasis.

Authors:  F W Orr; H H Wang; R M Lafrenie; S Scherbarth; D M Nance
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

4.  Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture.

Authors:  T J Ahonen; P L Härkönen; J Laine; H Rui; P M Martikainen; M T Nevalainen
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

5.  Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.

Authors:  Hongzhen Li; Tommi J Ahonen; Kalle Alanen; Jianwu Xie; Matthew J LeBaron; Thomas G Pretlow; Erica L Ealley; Ying Zhang; Martti Nurmi; Baljit Singh; Paula M Martikainen; Marja T Nevalainen
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

6.  Hormone regulation of human prostate in organ culture.

Authors:  M T Nevalainen; P L Härkönen; E M Valve; W Ping; M Nurmi; P M Martikainen
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

7.  Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Authors:  Stéphane Ansieau; Jeremy Bastid; Agnès Doreau; Anne-Pierre Morel; Benjamin P Bouchet; Clémence Thomas; Frédérique Fauvet; Isabelle Puisieux; Claudio Doglioni; Sara Piccinin; Roberta Maestro; Thibault Voeltzel; Abdelkader Selmi; Sandrine Valsesia-Wittmann; Claude Caron de Fromentel; Alain Puisieux
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

8.  Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA.

Authors:  A Nagafuchi; Y Shirayoshi; K Okazaki; K Yasuda; M Takeichi
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

Review 9.  Stepping out of the flow: capillary extravasation in cancer metastasis.

Authors:  Fayth L Miles; Freddie L Pruitt; Kenneth L van Golen; Carlton R Cooper
Journal:  Clin Exp Metastasis       Date:  2007-09-29       Impact factor: 5.150

10.  Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.

Authors:  Ayush Dagvadorj; Robert A Kirken; Benjamin Leiby; James Karras; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

View more
  52 in total

1.  Estimation of High-Dimensional Graphical Models Using Regularized Score Matching.

Authors:  Lina Lin; Mathias Drton; Ali Shojaie
Journal:  Electron J Stat       Date:  2016-04-06       Impact factor: 1.125

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

3.  Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Authors:  M Victoria Recouvreux; J Boyang Wu; Allen C Gao; Svetlana Zonis; Vera Chesnokova; Neil Bhowmick; Leland W Chung; Shlomo Melmed
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 4.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

5.  Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Authors:  Tuomas Mirtti; Benjamin E Leiby; Junaid Abdulghani; Elina Aaltonen; Miia Pavela; Anita Mamtani; Kalle Alanen; Lars Egevad; Torvald Granfors; Andreas Josefsson; Par Stattin; Anders Bergh; Marja T Nevalainen
Journal:  Hum Pathol       Date:  2012-09-29       Impact factor: 3.466

6.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 7.  Cell motility in cancer invasion and metastasis: insights from simple model organisms.

Authors:  Christina H Stuelten; Carole A Parent; Denise J Montell
Journal:  Nat Rev Cancer       Date:  2018-03-16       Impact factor: 60.716

8.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

9.  Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

Authors:  Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2019-09-23       Impact factor: 6.261

10.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.